A Supply Question Independent Clinics Cannot Solve With a Catalog

To a clinic buyer, supply can appear to be a simple question: is the item available? The FDA's compounding framework makes that answer incomplete. Under section 503A, eligibility to use a bulk drug substance depends on defined routes, including a qualifying monograph, an approved-drug component or a place on the 503A bulks list. The agency also describes documentation and manufacturer-registration requirements for bulk substances. Inclusion in an interim category is not the same as final placement on the statutory list.

There is a second question after the ingredient: what is the basis for compounding a particular finished product for a particular patient? The FDA's GLP-1 clarification focuses on individualized prescriptions and its restrictions on products that are essentially copies of commercially available drugs. In other words, an item can appear in a vendor's catalog without that alone answering whether an order fits the relevant framework.

This is not evidence of a shortage at any named supplier, nor a claim about a particular peptide's legal status. It is a narrower market observation: procurement and compliance cannot be separated by a product-search screen. A clinic designing a program needs a process that can accommodate those questions before it promises a fixed menu to patients.